Aim/Background: The anomalous production of dihydrotestosterone (DHT) observed in benign prostatic hyperplasia and prostate cancer particularly in tissues of the prostate gland. The primary male sex hormone, testosterone (T) is improved to a metabolite in cells by 5a-reductase (5aR) type II enzyme through NADPH. A metabolite is DHT which is more potent than T. Drug therapy is the best alternative for the treatment of benign prostatic hyperplasia (BPH). Drug therapy act by dropping the DHT formation through inhibiting the 5aR enzyme. Thus, this research work was undertaken to design a novel 5aR enzyme inhibitor by pharmacophore and Atom-based 3D QSAR technique. Materials and Methods: A dataset of twenty-nine ligands available with IC 50 chosen from the literature. Schrodinger molecular modelling software is having, phase 3.0 module implicated for generation of pharmacophore models. Results: Pharmacophore hypothesis with five features having two H-bond acceptors and three hydrophobic group was developed, i.e., AAHHH.715. This Pharmacophore hypothesis regarded as the finest one. This hypothesis resulted into statistically significant three-dimensional QSAR model. The statistical parameters were found to be 0.9804 as r2 value and 0.8321as q2 value. Out of 29 ligands, 23 ligands assigned as training set and 6 ligands as a test set. The squared correlation coefficient between training and test sets based on actual and predicted values were observed to be 0.96 and 0.87 respectively. Conclusion: The 5aR enzyme inhibitors predicting requirements can be done by this built model.
INTRODUCTION
Male secondary sex organs development and maintenance of secretory function are dependent on androgens. The androgen found most abundantly in serum is testosterone (T), produced by Leydig cells in testes controlled by the hypothalamus and pituitary gland. 1, 2 The T is improved to a metabolite in cells by 5a-reductase type II enzyme through NADPH. A metabolite is a dihydrotestosterone (DHT) which is more potent than T. 3 The 5a-reductase (5aR) isozymes are type I (5aR1) and type II (5aR2) identified by molecular cloning. 4 The distribution of 5aR is skin, kidney, liver and lungs have 5aR1 whereas 5aR2 is found in prostate, seminal vesicle, epididymis and hair follicles. 5 The anomalous production of DHT observed in BPH and prostate cancer particularly in prostate tissue. 6, 7 BPH has majorly two treatments available such as surgery and drug therapy. Clinically operation is effectual, but economical and postoperative complications are factors which limit it. 8, 9 Pharmacological (Drug) therapy, hence is the best alternative for the treatment of BPH. Drug therapy act by dropping the DHT formation through inhibiting the 5aR enzyme. Thus, a strategy proposed for controlling levels of DHT in the prostate by restricting 5aR activity (i.e., hindering the formation of DHT from T). 10 In due course of time, various potential 5aR inhibitors have synthesized and the even large number investigated. Some steroidal 5aR inhibiting molecules with higher binding affinities have produced which produces greater inhibition. 11 Commercially, finasteride 12 and epristeride 13 used as treatment options for BPH. These steroidal molecules have hormonal adverse effects. 14 Thus, nonsteroidal inhibitors are developed to overcome these adverse effects, but the activity of non-steroidal molecules as 5aR inhibition remain less. [15] [16] [17] [18] Apart from this, there are only a few drugs available to treat prostate diseases and existing drugs are becoming resistant. So, there is an urgent need for a drug which is highly specific and less toxic. Hence, this research work was undertaken to design a novel 5aR enzyme inhibitor by pharmacophore and Atom-based 3D QSAR technique.
MATERIAL AND METHODS

Data set selection
A dataset of twenty-nine ligands available with IC 50 for 5aR chosen from literature. Out of 29 ligands, 23 ligands assigned as training set and 6 ligands as test set. 19, 20 The model built by a training set and validation performed by the test set. The activity data, i.e. IC 50 values collected from the literature were transformed to PIC50 by choices present in the calculator.
Pharmacophore hypothesis generation:
Schrodinger molecular modeling software is having, Phase 3.0 module implicated for production of pharmacophore models. The minimum energy structural feature is required, to attain exact 3D descriptor values associated with QSAR studies. Maestro 2D sketch was used to draw the structures and these 2D structures converted to their respective 3D structures. OPLS force field was used to perform the geometry optimization. Two sets were formed, namely, training and test sets, of all ligands. PHASE uses a structure cleaning utility called ligprep, which adds hydrogen, generates stereoisomers and various conformers and predicts proper ionization states at a particular PH.PHASE provides two inbuilt approaches, employing the MacroModel conformational search engine. Due to the flexibility of ligands, all the possible conformers observed for each set of ligands and conformers close to the crystal structures could be sorted out. The conformational analysis was carried out using Monte Carlo Multiple Minimum methods.
The ligands were separated on the basis of the activity threshold value into active and inactive sets.
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Creation of Pharmacophore sites
Five-point pharmacophoric features defined the local chemical environment of selected ligands such as two H-bond acceptors (A) and three hydrophobic group (H). The inter-site distance and angles were used to develop pharmacophore.
Scoring pharmacophores on the basis of their activity threshold
The scoring and ranking of pharmacophore done to identify the best pharmacophore hypothesis. The configuration of site points and magnitude of vectors, selectivity and activity with overall conformational energies was considered to be active contributions for the scoring algorithm.
Identifying common pharmacophores
Once, the best hypothesis, AAHHH ( Figure 1A ) selection is over, afterward, it was further analyzed ( Table 1 ). The best hypothesis is the Pharmacophore, i.e. AAHHH. The pharmacophore, in this case, has unique characteristics as AA, i.e. two hydrogen bond acceptor and HHH, i.e. three hydrophobic groups. Pink sphere represents A with two arrows and H by green spheres ( Figure 1B) . Table 2 and Table 3 represents site scores of distances and angles respectively.
Building QSAR models
QSAR model was developed based on a selected common hypothesis by segregating the literature data into a training set as 70% and test set as 30% based on activity, structural similarity and functional group variation. PHASE provides binary options for the geometric alignment of 3dimensional structures. In the present study, an Atombased QSAR model used and this technique is a useful tool for the study of structure-activity relationships. The group of overlying van der Waal's spheres considered for every molecule in the study of atom based QSAR. Each atom placed into one of the three categories like positive ionic interactions, negative ionic interactions and hydrophobic non-polar interactions. The training set ligands arranged in regular Grid of cubes to develop best fit QSAR model. The cubes are labeled in a binary bit format to show different atom types and their features. The resulted data can be used to generate a partial least square regression model (PLS). The training set (23) was used to create atom-based QSAR models for the selected hypothesis using three PLS factors. The remaining molecules took under test set.
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RESULTS AND DISCUSSION
Undertaken research work intended to throw light on the three-dimensional structural properties of inhibitors of 5aR. The Phase module was used to carry out the pharmacophore modeling and QSAR studies of Schrodinger suite. This Phase module helps in envisaging the relative binding of test ligands to the active site of the receptor of the generated hypothesis. The pharmacophore dependent alignment was used to create the 3D-QSAR model for identification of structural features needed to inhibit 5aR.
The pharmacophore model generated by considering 29 compounds, having activity against 5-alpha reductase. These compounds have significant structural properties mandatory for binding to the receptor site. The most active compounds identified on the basis of having common properties as four minimum site and five maximum sites. The hypothesis AAHHH (Refer Table 1 ) was selected based on survival active and inactive scores. This pharmacophore hypothesis implicated in generating 3D QSAR model. Predictive ability of both training and test set implicated in assessing the 3D QSAR model (Table 4) . For a given set of PLS factors, the equation was analyzed on the basis of regression coefficient value and crossed validation coefficient value. The QSAR model based on the unique features of the atoms attached to the core ring system. The features studied are positive ionic interactions, negative ionic interactions and hydrophobic non-polar interactions (Figure 2 a,b and c). A dataset of twenty-nine ligands available with IC 50 chosen from literature. Pharmacophore hypothesis with five features having two H-bond acceptors and three hydrophobic group developed, i.e. AAHHH.715. This Pharmacophore hypothesis regarded as the finest hypothesis. The hypothesis resulted into statistically significant three-dimensional QSAR model. The statistical parameters were found to be 0.9804 as r 2 value and 0.8321as q 2 value (refer Table 5 ). The created model was applied effectively on both sets respectively. 
CONCLUSION
The squared correlation coefficient for the test set and training set was observed to be 0.87 and 0.96 respectively (actual v/s predicted values) ( Figure 3) . The model could be used to design potent inhibitors against 5aR.
